Beclomethasone dipropionate
As of the edition of 20 October 2026, Beclomethasone dipropionate is a small molecule: marketed, first approved in 1968 (ES); acts on NR3C1; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Small molecule
- Brand name
- Beclovent
- First approved
- 1 January 1968 (ES)
- Approvals on record
- 22 in 4 regions
- Holder of the most recent approval
- Chiesi Farmaceutici; 7 holders in all
- Registered trials
- 79, 6 stopped early
- Disease areas
- Lungs and airways; Immune system; Ear, nose and throat; Infections; Inherited and neonatal; Urinary and reproductive
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Chiesi Farmaceutici holds a later exclusivity on its own new formulation or combination product, ending 2029; it does not protect the original drug.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Beclomethasone dipropionate.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 17 | 12 | 2 | 2 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 13 | 11 | 0 | 2 |
| Phase 3 | 30 | 29 | 1 | 0 |
| Phase 4 | 14 | 11 | 1 | 2 |
| All trials | 79 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Acquired holder | 1998 to now |
| 3M | Later holder | 2000 to now |
| Teva | Acquired holder and Lead sponsor of trials | 2004 to now |
| Chiesi Farmaceutici | Later holder and Lead sponsor of trials | 2006 to now |
| GSK | Later holder and Lead sponsor of trials | 2006 to now |
| Norton Waterford | Later holder | 2017 to now |
| Merck & Co. | Applicant |